PAR-19-163 - Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)
NOT-DA-21-070- Notice to Extend the Expiration Date for PAR-19-163, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) intends to reissue PAR-19-163 "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)" to seek applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The Funding Opportunity Announcement (FOA) is expected to be published in January 2022 with an expected application due date in February 2022.
This FOA will utilize the R21 activity code.
Details of the planned FOA are provided below.
This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance-using behaviors and associated consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.
NIDA intends to commit $2 million in FY 2022.
4-6 awards
TBD
TBD
Applications are not being solicited at this time.
Please direct all inquiries to:
Marsha F. Lopez, Ph.D., M.H.S
National Institute on Drug Abuse (NIDA)
240-535-6066
Elizabeth Hoffman, Ph.D. (for ABCD applications)
National Institute on Drug Abuse (NIDA)
Telephone: 301.594.2265
Email: elizabeth.hoffman@nih.gov